{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T17:37:04Z","timestamp":1770831424482,"version":"3.50.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:00:00Z","timestamp":1681430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Fingolimod, an oral treatment for relapsing-remitting multiple sclerosis (RRMS), has been associated with a significant rebound in disease activity after therapy cessation. We described a patient with neuromyelitis optica spectrum disorder (NMOSD) who was previously diagnosed with RRMS and experienced fatal rebound syndrome after cessation of fingolimod.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case report<\/jats:title><jats:p>A 54-year-old woman, previously diagnosed with RRMS, experienced relapse after orthopedic surgery. The diagnosis was later revised to NMOSD based on a positive aquaporin-4 antibody. Three weeks after converting the immunomodulator from fingolimod to azathioprine, severe disease reactivation was observed. Considering the multiple new and enlarging magnetic resonance imaging lesions, the temporal relationship between fingolimod cessation and symptom onset, and the relatively low possibility of disease reactivation within a short time, the diagnosis of fingolimod withdrawal syndrome was proposed. Although immediate steroid pulse therapy and plasma exchange were performed, the patient eventually died owing to a fulminant clinical course.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Fingolimod withdrawal syndrome is well known in patients with multiple sclerosis (MS). It can also occur in patients with NMOSD. Recognizing patients with NMOSD who present with MS-like manifestations, and avoiding drugs that may be harmful to patients with NMOSD, are important.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1115120","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T04:29:56Z","timestamp":1681446596000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case Report: Severe rebound after withdrawal of fingolimod in a patient with neuromyelitis optica spectrum disorder"],"prefix":"10.3389","volume":"14","author":[{"given":"Wei","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung-Hsing","family":"Chou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fu-Chi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Kuang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Kai","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueh-Feng","family":"Sung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1756286419898594","DOI":"10.1177\/1756286419898594","article-title":"Short segment myelitis as the initial and only manifestation of aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorders","volume":"13","author":"Fang","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000034","article-title":"Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO","volume":"1","author":"Gelfand","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.216","article-title":"Failure of natalizumab to prevent relapses in neuromyelitis optica","volume":"69","author":"Kleiter","year":"2012","journal-title":"Arch Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1177\/1352458511431973","article-title":"Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder","volume":"18","author":"Min","year":"2012","journal-title":"Mult Scler"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2010.188","article-title":"Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers","volume":"67","author":"Palace","year":"2010","journal-title":"Arch Neurol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"101927","DOI":"10.1016\/j.msard.2020.101927","article-title":"Rebound of disease activity after fingolimod withdrawal: immunological and gene expression profiling","volume":"40","author":"Sacco","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","article-title":"Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis","volume":"33","author":"Chun","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2016.03.004","article-title":"Fingolimod-induced leukoencephalopathy in a patient with neuromyelitis optica spectrum disorder","volume":"7","author":"Yoshii","year":"2016","journal-title":"Mult Scler Relat Disord"},{"key":"B10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1471-2377-14-21","article-title":"Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension","volume":"14","author":"Kira","year":"2014","journal-title":"BMC Neurol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.5692\/clinicalneurol.53.513","article-title":"A case of neuromyelitis optica spectrum disorder developing a fulminant course with multiple white-matter lesions following fingolimod treatment","volume":"53","author":"Izaki","year":"2013","journal-title":"Rinsho Shinkeigaku"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/cen3.12032","article-title":"Longitudinally extensive spinal cord lesion after initiation, and multiple extensive brain lesions after cessation of fingolimod treatment in a patient with recurrent myelitis and anti-aquaporin 4 antibodies","volume":"4","author":"Tanaka","year":"2013","journal-title":"Clin Exp Neuroimmunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"102975","DOI":"10.1016\/j.msard.2021.102975","article-title":"Multiple sclerosis-like NMOSD patients suffer severe worsening of status after fingolimod initiation","volume":"52","author":"Bonnan","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2018.1531190","article-title":"Blood-brain barrier dysfunction in immuno-mediated neurological diseases","volume":"41","author":"Shimizu","year":"2018","journal-title":"Immunol Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13694","article-title":"Clinical activity after fingolimod cessation: disease reactivation or rebound","volume":"25","author":"Frau","year":"2018","journal-title":"Eur J Neurol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.0826","article-title":"Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment","volume":"73","author":"Hatcher","year":"2016","journal-title":"JAMA Neurol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s00415-021-10658-8","article-title":"What happens after fingolimod discontinuation? a multicentre real-life experience","volume":"269","author":"Landi","year":"2022","journal-title":"J Neurol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/NRL.0000000000000154","article-title":"Factors predictive of severe multiple sclerosis disease reactivation after fingolimod cessation","volume":"23","author":"Uygunoglu","year":"2018","journal-title":"Neurologist"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-019-00160-9","article-title":"Fingolimod rebound: a review of the clinical experience and management considerations","volume":"8","author":"Barry","year":"2019","journal-title":"Neurol Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00782","article-title":"Rebound after fingolimod and a single daclizumab injection in a patient retrospectively diagnosed with NMO spectrum disorder-MRI apparent diffusion coefficient maps in differential diagnosis of demyelinating CNS disorders","volume":"9","author":"Wagner","year":"2018","journal-title":"Front Neurol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0b013e3182a78f82","article-title":"Simultaneous PML-IRIS and myelitis in a patient with neuromyelitis optica spectrum disorder","volume":"3","author":"Flanagan","year":"2013","journal-title":"Neurol Clin Pract"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1115120\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T04:29:58Z","timestamp":1681446598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1115120\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,14]]},"references-count":21,"alternative-id":["10.3389\/fimmu.2023.1115120"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1115120","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,14]]},"article-number":"1115120"}}